WOBE437 is a selective endocannabinoid reuptake inhibitor (SERI) which has been used in scientific research. It is a highly potent and selective endocannabinoid reuptake inhibitor, with an IC50Tooltip half-maximal inhibitory concentration of 10 nM in terms of this action. The drug produces anxiolytic-like, anti-inflammatory, analgesic, antiallodynic, and muscle relaxant effects in rodents. These effects are mediated by increased endocannabinoid levels, including of anandamide (AEA) and 2-arachidonylglycerol (2-AG), and are dependent on cannabinoid receptors, for instance the cannabinoid CB1 receptor. Conversely, WOBE437 did not produce catalepsy, affect locomotor activity, or produce the typical sedation of cannabinoid CB1 receptor agonists. The drug also showed effectiveness in an animal model of multiple sclerosis. Originally believed to be selective, off-target activities of WOBE437 have subsequently been identified and described. WOBE437 is orally bioavailable in rodents. Numerous analogues of WOBE437 have been explored in search of candidates with better drug-like properties, though a series of almost 80 compounds found none that were more potent than WOBE437 itself. WOBE437 was first described in the scientific literature by 2013.
See also Endocannabinoid reuptake inhibitor SYT-510
References

